Skip to main content
. 2015 Jun 1;5:10760. doi: 10.1038/srep10760

Figure 5. Experimental validation of the predicted β-arrestin-Raf1 and β-arrestin-ERK2 interaction sites.

Figure 5

A) Equal amounts of GST-Raf1-RBD fusion protein were incubated with 25 ng of β-arrestin 1 and with or without 0.5mM of the indicated peptide. B) Representative blot for β-arrestin-Raf1 interaction site sequentially probed with anti-β-arrestin and anti-GST antibodies. B) Equal amounts of GST-ERK2 fusion protein were incubated with 25 ng of β-arrestin 1 and with or without 0.5mM of the indicated peptide. Representative blot for β-arrestin-ERK2 interaction site sequentially probed with anti-β-arrestin and anti-ERK antibodies. Immunoblots were quantified using Odyssey software and data were expressed as the ratio of β-arrestin 1 over GST-Raf1-RBD or GST-ERK respectively. The maximum response measured with the Control peptide was chosen as 100%. Data represent means ± SEM from three independent experiments. *,**: p < 0.05 specific peptides versus control peptides.